Early Response in Albuminuria and Long-Term Kidney Protection during Treatment with an Endothelin Receptor Antagonist: A Prespecified Analysis from the SONAR Trial.
Hiddo J L HeerspinkDi XieGeorge L BakrisRicardo Correa-RotterFan-Fan HouDalane W KitzmanDonald KohanHirofumi MakinoJohn J V McMurrayVlado PerkovicEllen BurgessHans-Henrik ParvingDick de Zeeuwnull nullPublished in: Journal of the American Society of Nephrology : JASN (2021)
Our findings do not support UACR response as a causal predictor of atrasentan's treatment effect. However, the variable trajectory in UACR with placebo, aspects of the trial design, day-to-day variability in albuminuria, and potential long-lasting effects of atrasentan may have contributed.